GlassScriptPhysician profile
Arnold Clive Cinman
NPI 1801867163
$11,117.67
in general payments reported to CMS, 2019-2025
30 companies · $4,691 in 2025
The $4,691 reported for 2025 was more than what 90% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $171 · 2021: $785 · 2022: $421 · 2023: $854 · 2024: $3,183 · 2025: $4,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,700 · Food and Beverage: $2,367 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,700.00 |
| Food and Beverage | $2,367.45 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,661.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $3,937.21 | 2025 | |
| Ferring Pharmaceuticals INC. | $2,773.58 | 2024-2025 | Adstiladrin |
| Janssen Biotech, INC. | $1,019.42 | 2019-2025 | Erleada, Akeega |
| Pfizer INC. | $590.00 | 2019-2025 | |
| Astellas Pharma US INC | $524.97 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $406.14 | 2019-2025 | Provenge |
| Abbvie INC. | $243.21 | 2021-2025 | Botox |
| Teleflex LLC | $216.70 | 2021-2023 | Urolift |
| Myriad Genetic Laboratories, INC. | $158.64 | 2021-2025 | Prolaris |
| Blue Earth Diagnostics | $145.71 | 2021-2025 | Posluma |
| Coloplast Corp | $136.41 | 2021 | |
| Telix Pharmaceuticals | $118.36 | 2024-2025 | Illuccix |
| Dornier Medtech America, INC | $102.06 | 2025 | Dornier Medtech |
| Comsort, INC | $100.00 | 2019 | |
| Merck Sharp & Dohme LLC | $89.38 | 2019-2024 | Keytruda, Welireg |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Profound Medical Corp. | $88.20 | 2023 | Tulsa-Pro |
| Sumitomo Pharma America, INC. | $79.04 | 2024-2025 | Orgovyx |
| Astrazeneca Pharmaceuticals LP | $73.12 | 2021-2023 | Lynparza |
| Myovant Sciences INC. | $70.57 | 2021-2022 | |
| Immunitybio, INC. | $45.30 | 2025 | |
| Boston Scientific Corporation | $32.06 | 2019-2021 | |
| Amgen INC. | $28.80 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.01 | 2025 | |
| Progenics Pharmaceuticals, INC. | $24.92 | 2023 | Pylarify |
| Abc Home Medical Supply, INC. | $23.76 | 2025 | |
| Axonics, INC. | $22.39 | 2022 | |
| Karl Storz Endoscopy-America | $22.33 | 2019 | |
| Hollister Incorporated | $11.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnold Cinman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.